Dr. Klings is an Associate Professor in the Department of Medicine. She is the Director of the Center for Excellence in Sickle Cell Disease and the Director of the Pulmonary Hypertension at BUSM/Boston Medical Center. She has an outpatient clinical practice focused on patients with pulmonary hypertension and those with pulmonary complications of sickle cell disease. She attends in the Medical Intensive Care Unit and on the Pulmonary Hypertension Consultation Service at Boston Medical Center. As Director of the largest sickle cell center in New England, Dr. Klings has created numerous new clinical programs for our patients and has expanded the clinical trials program.
Dr. Klings’ research since fellowship has focused on pathogenesis of pulmonary vascular complications of sickle cell disease. She is an NIH-funded Principal Investigator .in the Pulmonary Center collaborating with numerous other investigators across the medical campus. She has phenotypically screened over 200 sickle cell patients at Boston Medical Center for the presence of pulmonary hypertension and currently investigating the roles of disease modulators including sleep-disordered breathing and venous thromboembolism in the endothelial and vascular dysfunction these patients experience. Known internationally as a leader in the care and treatment of patients with sickle cell disease, she was first author of the American Thoracic Society sponsored clinical guidelines for Diagnosis and Treatment of Pulmonary Hypertension in Sickle Cell Disease. She recently chaired an ATS sponsored workshop to define clinical and research priorities in sickle cell lung disease and serves on the NHLBI Sickle Cell Disease Advisory Committee.
- Member, Pulmonary Center, Boston University
- Program Director, Center of Excellence in Sickle Cell Disease, Boston University
- Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
- New York University School of Medicine, MD
- New York University, BA
- Published on 7/1/2022
Johnson SW, Gillmeyer KR, Bolton RE, McCullough MB, Qian SX, Maron BA, Klings ES, Wiener RS. Variable Monitoring of Veterans with Group 3 Pulmonary Hypertension Treated with Off-Label Pulmonary Vasodilator Therapy. Ann Am Thorac Soc. 2022 Jul; 19(7):1236-1239. PMID: 35312466.
- Published on 6/9/2022
Lui JK, Gillmeyer KR, Sangani RA, Smyth RJ, Gopal MDM, Trojanowski MA, Bujor AM, Wiener RS, LaValley MP, Klings ES. A Multimodal Prediction Model for Diagnosing Pulmonary Hypertension in Systemic Sclerosis. Arthritis Care Res (Hoboken). 2022 Jun 09. PMID: 35678779.
- Published on 4/15/2022
Nakagawa A, Cooper MK, Kost-Alimova M, Berstler J, Yu B, Berra L, Klings ES, Huang MS, Heeney MM, Bloch DB, Zapol WM. High-Throughput Assay to Screen Small Molecules for Their Ability to Prevent Sickling of Red Blood Cells. ACS Omega. 2022 Apr 26; 7(16):14009-14016. PMID: 35559170.
- Published on 4/5/2022
Lui JK, Sangani RA, Chen CA, Bujor AM, Trojanowski MA, Gopal DM, LaValley MP, Soylemez Wiener R, Klings ES. Prognostic Value of Cardiac Axis Deviation in Systemic Sclerosis-Related Pulmonary Hypertension. Arthritis Care Res (Hoboken). 2022 Jul; 74(7):1219-1226. PMID: 34085410.
- Published on 2/16/2022
Klings ES, Steinberg MH. Acute chest syndrome of sickle cell disease: genetics, risk factors, prognosis, and management. Expert Rev Hematol. 2022 Feb; 15(2):117-125. PMID: 35143368.
- Published on 7/12/2021
Moy ML, Wayne PM, Litrownik D, Beach D, Klings ES, Davis RB, Pinheiro A, Yeh GY. Long-term Exercise After Pulmonary Rehabilitation (LEAP): a pilot randomised controlled trial of Tai Chi in COPD. ERJ Open Res. 2021 Jul; 7(3). PMID: 34262967.
- Published on 6/24/2021
Belok SH, Bosch NA, Klings ES, Walkey AJ. Evaluation of leukopenia during sepsis as a marker of sepsis-defining organ dysfunction. PLoS One. 2021; 16(6):e0252206. PMID: 34166406.
- Published on 6/9/2021
Kraemer KM, Litrownik D, Moy ML, Wayne PM, Beach D, Klings ES, Reyes Nieva H, Pinheiro A, Davis RB, Yeh GY. Exploring Tai Chi Exercise and Mind-Body Breathing in Patients with COPD in a Randomized Controlled Feasibility Trial. COPD. 2021 06; 18(3):288-298. PMID: 34106027.
- Published on 4/15/2021
Cramer-Bour C, Ruhl AP, Nouraie SM, Emeh RO, Ruopp NF, Thein SL, Weir NA, Klings ES. Long-term tolerability of phosphodiesterase-5 inhibitors in pulmonary hypertension of sickle cell disease. Eur J Haematol. 2021 Jul; 107(1):54-62. PMID: 33650125.
- Published on 4/2/2021
Cramer-Bour C, Peterson J, Walsh B, Klings ES. Common Complications of Sickle Cell Disease: A Simulation-Based Curriculum. MedEdPORTAL. 2021 04 02; 17:11139. PMID: 33851012.
View 68 more publications: View full profile at BUMC